{"id":220358,"date":"2023-05-05T14:54:47","date_gmt":"2023-05-05T06:54:47","guid":{"rendered":"http:\/\/www.namnewsnetwork.org\/?p=220358"},"modified":"2023-05-05T14:54:47","modified_gmt":"2023-05-05T06:54:47","slug":"george-clinical-selected-as-cro-for-hummingbird-biosciences-phase-1-oncology-trials-in-australia","status":"publish","type":"post","link":"http:\/\/namnewsnetwork.org\/?p=220358","title":{"rendered":"George Clinical Selected as CRO for Hummingbird Bioscience\u2019s Phase 1 Oncology Trials in Australia"},"content":{"rendered":"\n<p><strong>SYDNEY, May 5 (Bernama-GLOBE NEWSWIRE) &#8212;<\/strong>&nbsp;George Clinical announces that the company has initiated preparations in Australia for two oncology Phase 1b trials that will examine a Hummingbird Bioscience precision therapy program targeting HER3, a potent driver of tumor growth and resistance against cancer drugs, in biomarker-selected patient populations, including lung cancer. George Clinical is providing its full-service clinical research organization (CRO) expertise for the Hummingbird Bioscience-sponsored trials.<\/p>\n\n\n\n<p>Molecular-matched therapies have revolutionized cancer treatment with the capability to inhibit specific molecular targets leading to better therapeutic responses and less system toxicity. Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing biologic medicines for hard-to-treat diseases, is bringing its clinical-stage anti-HER3 drug known as HMBD-001 into molecular-matched patient trials in Australia for the first time.<\/p>\n\n\n\n<p><a href=\"http:\/\/mrem.bernama.com\/viewsm.php?idm=46023\">http:\/\/mrem.bernama.com\/viewsm.php?idm=46023<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SYDNEY, May 5 (Bernama-GLOBE NEWSWIRE) &#8212;&nbsp;George Clinical announces that the company has initiated preparations in Australia for two oncology Phase 1b trials that will examine a Hummingbird Bioscience precision therapy program targeting HER3, a potent driver of tumor growth and resistance against cancer drugs, in biomarker-selected patient populations, including lung cancer. George Clinical is providing [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[315],"tags":[],"_links":{"self":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/220358"}],"collection":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=220358"}],"version-history":[{"count":1,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/220358\/revisions"}],"predecessor-version":[{"id":220359,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/220358\/revisions\/220359"}],"wp:attachment":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=220358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=220358"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=220358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}